MedTrace Logo

A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors

NCT04875806 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-04-22

Study results available
· View outcomes & findings →

Summary

This research study is studying a new drug, NC762, as a possible treatment for advanced or metastatic solid tumors.

Conditions

Interventions

DRUG

NC762

NC762 is an experimental antibody drug that may make the immune response more active against cancer

Sponsors & Collaborators

  • NextCure, Inc.

    lead INDUSTRY

Principal Investigators

  • Han Myint, MD · NextCure, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-30
Primary Completion
2024-01-30
Completion
2024-01-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04875806 on ClinicalTrials.gov